Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer

Anticancer Research

Volumn 25, Issue 3 C, 2005, Pages 2429-2434

  Hotta, Katsuyuki ^a   Takigawa, Nagio ^b   Kiura, Katsuyuki ^a   Tabata, Masahiro ^a   Umemura, Shigeki ^a   Ogino, Atsuko ^a   Uchida, Akiko ^a   Bessho, Akihiro ^c   Segawa, Yoshihiko ^c   Shinkai, Tetsu ^c   Nogami, Naoyuki ^c   Harita, Shingo ^d   Okimoto, Niro ^e   Ueoka, Hiroshi ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Department of Internal Medicine   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^d CHUGOKU CENTRAL HOSPITAL   (Japan)

^e KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Amrubicin; Irinotecan; Non platinum regimen; Non small cell lung cancer; Phase I study; Topoisomerase inhibitor

Indexed keywords

AMRUBICIN; CARBOPLATIN; GEMCITABINE; IRINOTECAN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPONATREMIA; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEMATOLOGIC DISEASES; HUMANS; HYPONATREMIA; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 22944441618     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Smith W and Khuri FR: The care of the lung cancer patient in the 21st century: a new age. Semin Oncol 31(2 Suppl 4): 11-15, 2004.
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
3. Bunn PA: Chemotherapy for advanced non-small cell lung cancer: who, what, when, why? J Clin Oncol 20: 23s-33s, 2002.
4. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y et al: Phase II study of irinotecan, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16-20, 1992.
5. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N et al: Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small cell lung cancer. Br J Cancer 88: 335-341, 2003.
6. Negoro S, Fukuoka M, Nakamura S, Ikegami H, Sugiura T, Ariyoshi Y et al: Phase I-II study of amrubicin (SM-5887), a novel 9-amino-anthracycline, by i.v. administration for 3 consecutive days in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 14: (abstr 1105), 1995.
7. Tan KB, Mattern MR, Eng WK, McCabe FL and Johnson RK: Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732-1735, 1989.
8. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF and Tsuruo T: Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962-7965, 1990.
9. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M et al: Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial. Lancet 357: 1478-1484, 2001.
10. Mountain CF and Dresler CM: Regional lymph node classification for lung cancer staging. Chest 111: 1718-23, 1997.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
12. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
13. Theodoulou M and Hudis C: Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 100: 2052-2063, 2004.
14. Noda T, Watanabe T, Kohda A, Hosokawa S and Suzuki T: Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16: 121-128, 1998.
15. Yana T, Negoro S, Takada Y, Yokota S and Fukuoka M: Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): A West Japan Lung Cancer Group Trial. Proc Am Soc Clin Oncol 17: 450a (abstr 1734), 1998.
16. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y et al: Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small cell lung cancer (ED-SCLC). Ann Oncol 16: 430-436, 2005.
17. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 83: 1164-1168, 1991.
18. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M et al: Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604-610, 1992.
19. Kaufman SH: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129-1136, 1991.
20. Bertrand R, O'Connor PM, Kerrigan D and Pommier Y: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A: 743-748, 1992.
21. Masuda N, Matsui K, Negoro S, Takifuji N, Takeda K, Yana T et al: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16: 3329-3334, 1998.
22. Oshita F, Noda K, Nishiwaki Y, Fujita A, Kurita Y, Nakabayashi T et al: Phase II study of irinotecan and etoposide in patients with metastatic non-small cell lung cancer. J Clin Oncol 75: 304-309, 1997.
23. Evans WK, Osoba D, Feld R, Shepherd FA, Bazos MJ and DeBoer G: Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small cell lung cancer. J Clin Oncol 3: 65-71, 1985.
24. Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M et al: Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 98: 310-315, 2002.